PAION Announces Successful Completion Of Phase I Study With The Sedative/Anaesthetic CNS 7056
The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8; London AIM: PAI) today announces that it has successfully completed a Phase I study with its intravenous sedative/anaesthetic CNS 7056.